He, Gui-Wei

仰望星空 脚踏实地

He, Gui-Wei


Institute of Infectious Diseases

Junior Principal Investigator


  • 2023 - Present

    Shenzhen Bay laboratory         Junior Principle Investigator

  • 2019 - 2022

    Hubrecht Institute         Postdoc

  • 2012 - 2019

    Friedrich-Alexander-Universität Erlangen-Nürnberg         PhD, Postdoc

  • 2004 - 2011

    Jinan University, Guangzhou         Bachelor of Science, Master of Science

Research Areas

We are interested in understanding the fundamental biological principles underlying tissue development and disease, particularly infectious disease and cancer. We aim to establish the most advanced organoid culture systems to model these human pathologies and to reveal mechanisms that prevent or drive disease, with the ultimate goals of identifying novel therapeutic strategies.


Dr. He Gui-Wei received his PhD degree with summa cum laude from the University of Erlangen-Nuremberg in Germany in 2018. Then Dr. He joined Professor Hans Clevers laboratory at the Hubrecht Institute, where he developed a next-generation human intestinal organoid model and used this new model system to study human intestinal development and diseases. Dr. He's studies were published in high-profile journals, including Cell Stem Cell, Gut and Journal of Experimental Medicine.


In this study, we establish an optimized human intestinal organoid model and discover the mechanisms of interleukin-22-dependent Paneth cell formation.


• 2017 Chinese Government Award for Outstanding Self-financed Students Abroad

Related News

Optimization of human small intestinal organoids

Selected Publications

1. He, G. W.#; Lin, L.#; DeMartino, J.; Zheng, X.; Staliarova, N.; Dayton, T.; Begthel, H.; Wetering, W.; Bodewes, E.; Zon, J. E.; Tans, S.; Lopez-Iglesias, C.; Peters, P. J.; Wu, W.; Kotlarz, D.; Klein, C.; Margaritis, T.; Holstege, F.; Clevers, H., Optimized human intestinal organoid model reveals interleukin-22-dependency of Paneth cell formation. Cell Stem Cell. 2022.

2. He, G. W.; Gunther, C.; Thonn, V.; Yu, Y. Q.; Martini, E.; Buchen, B.; Neurath, M. F.; Sturzl, M.; Becker, C., Regression of apoptosis-resistant colorectal tumors by induction of necroptosis in mice. J Exp Med 2017, 214 (6), 1655-1662.

3. He, G. W.#; Gunther, C.#; Kremer, A. E.; Thonn, V.; Amann, K.; Poremba, C.; Neurath, M. F.; Wirtz, S.; Becker, C., PGAM5-mediated programmed necrosis of hepatocytes drives acute liver injury. Gut 2017, 66 (4), 716-723.

4. Gunther, C.; He, G. W.; Kremer, A. E.; Murphy, J. M.; Petrie, E. J.; Amann, K.; Vandenabeele, P.; Linkermann, A.; Poremba, C.; Schleicher, U.; Dewitz, C.; Krautwald, S.; Neurath, M. F.; Becker, C.; Wirtz, S., The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis. J Clin Invest 2016, 126 (11), 4346-4360.

5. Driehuis, E.; Kolders, S.; Spelier, S.; Lohmussaar, K.; Willems, S. M.; Devriese, L. A.; de Bree, R.; de Ruiter, E. J.; Korving, J.; Begthel, H.; van Es, J. H.; Geurts, V.; He, G. W.; van Jaarsveld, R. H.; Oka, R.; Muraro, M. J.; Vivie, J.; Zandvliet, M.; Hendrickx, A. P. A.; Iakobachvili, N.; Sridevi, P.; Kranenburg, O.; van Boxtel, R.; Kops, G.; Tuveson, D. A.; Peters, P. J.; van Oudenaarden, A.; Clevers, H., Oral Mucosal Organoids as a Potential Platform for Personalized Cancer Therapy. Cancer Discov 2019, 9 (7), 852-871.